Positive News Sentiment NASDAQ:EDIT Editas Medicine Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Editas Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $12.59 +0.76 (+6.42%) (As of 07/1/2022 08:44 PM ET) Add Compare Share Today's Range$11.79▼$12.6850-Day Range$9.99▼$15.8152-Week Range$9.59▼$73.03Volume1.44 million shsAverage Volume1.81 million shsMarket Capitalization$864.19 millionP/E RatioN/ADividend YieldN/APrice Target$33.20 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Editas Medicine MarketRank™ ForecastAnalyst RatingHold2.22 Rating ScoreUpside/Downside163.7% Upside$33.20 Price TargetShort InterestBearish21.30% of Shares Sold ShortDividend StrengthN/ASustainability-0.91Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$86.23 K Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.41) to ($3.38) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.24 out of 5 starsMedical Sector230th out of 1,412 stocksBiological Products, Except Diagnostic Industry30th out of 215 stocks 3.1 Analyst's Opinion Consensus RatingEditas Medicine has received a consensus rating of Hold. The company's average rating score is 2.22, and is based on 4 buy ratings, 3 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $33.20, Editas Medicine has a forecasted upside of 163.7% from its current price of $12.59.Amount of Analyst CoverageEditas Medicine has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted21.30% of the outstanding shares of Editas Medicine have been sold short.Short Interest Ratio / Days to CoverEditas Medicine has a short interest ratio ("days to cover") of 8.8.Change versus previous monthShort interest in Editas Medicine has recently increased by 1.32%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldEditas Medicine does not currently pay a dividend.Dividend GrowthEditas Medicine does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEditas Medicine has received a 71.98% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Editas Medicine is -0.91. Previous Next 2.7 News and Social Media Coverage News SentimentEditas Medicine has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Editas Medicine this week, compared to 2 articles on an average week.Search InterestOnly 20 people have searched for EDIT on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.MarketBeat FollowsOnly 9 people have added Editas Medicine to their MarketBeat watchlist in the last 30 days. This is a decrease of -44% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Editas Medicine insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $86,233.00 in company stock.Percentage Held by InsidersOnly 0.94% of the stock of Editas Medicine is held by insiders.Percentage Held by Institutions75.48% of the stock of Editas Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Editas Medicine are expected to grow in the coming year, from ($3.41) to ($3.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Editas Medicine is -4.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Editas Medicine is -4.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEditas Medicine has a P/B Ratio of 1.56. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive EDIT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Editas Medicine and its competitors with MarketBeat's FREE daily newsletter. Email Address About Editas Medicine (NASDAQ:EDIT) StockEditas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.Read More EDIT Stock News HeadlinesJune 18, 2022 | americanbankingnews.comMark S. Shearman Sells 5,145 Shares of Editas Medicine, Inc. (NASDAQ:EDIT) StockJune 12, 2022 | americanbankingnews.comEditas Medicine (NASDAQ:EDIT) Stock Price Down 8%June 2, 2022 | bizjournals.comThe Petri Dish: Former Editas CEO joins European venture firmMay 18, 2022 | finance.yahoo.comEditas Medicine Presents Data on SLEEK Gene Editing Technology at the American Society of Gene and Cell Therapy Annual MeetingMay 13, 2022 | seekingalpha.comEditas Medicine granted Orphan Drug Designation for beta thalassemia candidateMay 13, 2022 | finance.yahoo.comEditas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Beta ThalassemiaMay 4, 2022 | investing.comEditas Medicine Tops Q1 EPS by 5cMay 4, 2022 | seekingalpha.comEditas Medicine, Inc. (EDIT) CEO Jim Mullen on Q1 2022 Results - Earnings Call TranscriptMay 3, 2022 | seekingalpha.comEditas Medicine Q1 2022 Earnings PreviewMay 2, 2022 | nasdaq.comEditas Medicine vs. Ethereum: Price Relationship Crosses ThresholdApril 26, 2022 | markets.businessinsider.comEditas Medicine's EDIT-301 receives FDA Rare Pediatric Disease designation for Beta ThalassemiaApril 20, 2022 | ca.finance.yahoo.comGlobal CRISPR & Cas Genes Market Research Report to 2027 - Featuring Addgene, Danaher and Editas Medicine Among Others - ResearchAndMarkets.comApril 18, 2022 | seekingalpha.comEditas Medicine stock falls ~8% after Baird cuts price targetApril 15, 2022 | marketwatch.comEditas Medicine Names Gilmore O'Neill as President, CEO >EDITApril 14, 2022 | finance.yahoo.comEditas Medicine Appoints Gilmore O’Neill as Chief Executive OfficerApril 11, 2022 | msn.comCramer's lightning round: Editas Medicine is not a buyApril 11, 2022 | seekingalpha.comEditas begins dosing pediatric patient in trial to treat eye disorderApril 8, 2022 | finance.yahoo.comEditas Medicine Reports Engineered iNK Cell Preclinical Data at American Association for Cancer Research Annual MeetingMarch 29, 2022 | finance.yahoo.comGene-Editing Technologies, Fluid Mechanics Breakthroughs, and Solutions to Unfathomable Mathematical Equations Recognized by King Faisal PrizeMarch 1, 2022 | seekingalpha.comEditas rides on patent win for Broad Institute in CRSPR gene editingMarch 1, 2022 | businessinsider.comAfter falling behind gene-editing rivals, Editas just got a much-needed win in the courtroom. Here's how it could shake up the CRISPR landscape.March 1, 2022 | finance.yahoo.comEditas Medicine Stock Jumps As Patent Office Rules In Favor Of Broad's CRISPR PatentsFebruary 28, 2022 | finance.yahoo.comEditas Medicine (NASDAQ:EDIT) adds US$129m to market cap in the past 7 days, though investors from a year ago are still down 61%February 25, 2022 | benzinga.comSVB Leerink Maintains Market Perform on Editas Medicine, Lowers Price Target to $27February 25, 2022 | markets.businessinsider.comExpert Ratings For Editas MedicineSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EDIT CUSIPN/A CIK1650664 Webwww.editasmedicine.com Phone(617) 401-9000FaxN/AEmployees264Year FoundedN/ACompany Calendar Last Earnings5/04/2022Today7/04/2022Next Earnings (Estimated)8/03/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$33.20 High Stock Price Forecast$80.00 Low Stock Price Forecast$8.00 Forecasted Upside/Downside+163.7%Consensus RatingHold Rating Score (0-4)2.22222222222222 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.730010) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-192.50 million Net Margins-721.60% Pretax Margin-721.60% Return on Equity-32.88% Return on Assets-26.87% Debt Debt-to-Equity RatioN/A Current Ratio13.62 Quick Ratio13.62 Sales & Book Value Annual Sales$25.54 million Price / Sales33.84 Cash FlowN/A Price / Cash FlowN/A Book Value$8.09 per share Price / Book1.56Miscellaneous Outstanding Shares68,641,000Free Float67,996,000Market Cap$864.19 million OptionableOptionable Beta1.94 Editas Medicine Frequently Asked Questions Should I buy or sell Editas Medicine stock right now? 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last year. There are currently 2 sell ratings, 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Editas Medicine stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EDIT, but not buy additional shares or sell existing shares. View analyst ratings for Editas Medicine or view top-rated stocks. What is Editas Medicine's stock price forecast for 2022? 9 analysts have issued 1-year target prices for Editas Medicine's stock. Their EDIT stock forecasts range from $8.00 to $80.00. On average, they anticipate Editas Medicine's share price to reach $33.20 in the next twelve months. This suggests a possible upside of 163.7% from the stock's current price. View analysts' price targets for Editas Medicine or view top-rated stocks among Wall Street analysts. How has Editas Medicine's stock performed in 2022? Editas Medicine's stock was trading at $26.55 at the beginning of 2022. Since then, EDIT stock has decreased by 52.6% and is now trading at $12.59. View the best growth stocks for 2022 here. When is Editas Medicine's next earnings date? Editas Medicine is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022. View our earnings forecast for Editas Medicine. How were Editas Medicine's earnings last quarter? Editas Medicine, Inc. (NASDAQ:EDIT) announced its earnings results on Wednesday, May, 4th. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.81) by $0.07. The company earned $6.80 million during the quarter, compared to analysts' expectations of $3.85 million. Editas Medicine had a negative trailing twelve-month return on equity of 32.88% and a negative net margin of 721.60%. The company's quarterly revenue was up 4.6% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.86) earnings per share. View Editas Medicine's earnings history. Who are Editas Medicine's key executives? Editas Medicine's management team includes the following people: Mr. James C. Mullen, Exec. Chairman (Age 63, Pay $1.01M) (LinkedIn Profile)Ms. Michelle Robertson, CFO, Principal Accounting Officer, Treasurer & Assistant Sec. (Age 55, Pay $641.74k)Dr. Mark S. Shearman, Exec. VP & Chief Scientific Officer (Age 62, Pay $639.89k)Dr. Bruce E. Eaton Ph.D., Exec. VP & Chief Bus. Officer (Age 68, Pay $1.09M)Dr. Gilmore O'Neill, Pres & CEO (Age 58)Dr. Feng Zhang Ph.D., Co-Founder & Scientific Advisory Board MemberDr. George McDonald Church Ph.D., Co-Founder & Scientific Advisory Board Member (Age 68)Dr. J. Keith Joung M.D., Ph.D., Co-Founder & Scientific Advisory Board MemberDr. David R. Liu Ph.D., Co-Founder & Scientific Advisory Board MemberMr. Harry R. Gill III, Sr. VP of Operations (Age 61) Who are some of Editas Medicine's key competitors? Some companies that are related to Editas Medicine include Vir Biotechnology (VIR), Abcam (ABCM), Beam Therapeutics (BEAM), Bavarian Nordic A/S (BVNRY), Fate Therapeutics (FATE), Twist Bioscience (TWST), BioCryst Pharmaceuticals (BCRX), Relay Therapeutics (RLAY), Iovance Biotherapeutics (IOVA), Krystal Biotech (KRYS), Allogene Therapeutics (ALLO), Immunocore (IMCR), ImmunityBio (IBRX), Revolution Medicines (RVMD) and Recursion Pharmaceuticals (RXRX). View all of EDIT's competitors. What other stocks do shareholders of Editas Medicine own? Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Micron Technology (MU), Intellia Therapeutics (NTLA), Square (SQ), Advanced Micro Devices (AMD), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO) and Skyworks Solutions (SWKS). When did Editas Medicine IPO? (EDIT) raised $100 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers. What is Editas Medicine's stock symbol? Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT." How do I buy shares of Editas Medicine? Shares of EDIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Editas Medicine's stock price today? One share of EDIT stock can currently be purchased for approximately $12.59. How much money does Editas Medicine make? Editas Medicine (NASDAQ:EDIT) has a market capitalization of $864.19 million and generates $25.54 million in revenue each year. The company earns $-192.50 million in net income (profit) each year or ($2.730010) on an earnings per share basis. How many employees does Editas Medicine have? Editas Medicine employs 264 workers across the globe. How can I contact Editas Medicine? Editas Medicine's mailing address is 11 Hurley Street, Cambridge MA, 02141. The official website for Editas Medicine is www.editasmedicine.com. The company can be reached via phone at (617) 401-9000 or via email at mark.mullikin@editasmed.com. This page (NASDAQ:EDIT) was last updated on 7/4/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
